23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Spyre Therapeutics, Inc. › 2025-2026

Spyre Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Spyre Therapeutics, Inc.’s Form 8-K, filed May 29, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Reported items
  • 220Asset managers, any item
  • 1,672Fund votes
  • May 27, 2026Meeting date

Results at a glance

Meeting of May 27, 2026: 6 items on Spyre Therapeutics, Inc.’s Form 8-K, filed May 29, 2026: 3 approved · 3 passed (calculated).

Dissent

Notable dissent: 1 director (14.9% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Tang Capital (13F, 2.0%, as of September 30, 2026)

Explore Spyre Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Spyre Therapeutics, Inc.

These tallies are Spyre Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Spyre Therapeutics, Inc. — official shareholder meeting results, meeting held May 27, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Mark McKenna 65,608,709---- 1,329,4891,500,346 98%Passed (calculated)—
Elect Director: Cameron Turtle, D. Phil. 66,176,245---- 761,9531,500,346 99%Passed (calculated)—
Elect Director: Laurie Stelzer 56,954,664---- 9,983,5341,500,346 85%Passed (calculated)—
2. On a non-binding, advisory basis, the compensation of the Company's named executive officers 62,075,4594,760,373102,366 --1,500,346 93%Approved—
3. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 68,430,5666707,308 --0 99.9%Approved—
4. Company's AR ESPP 66,885,86445,5426,792 --1,500,346 99.9%Approved—

Source: Spyre Therapeutics, Inc., Form 8-K, filed with the SEC on May 29, 2026 — read the filing on EDGAR.

How asset managers voted at the Spyre Therapeutics, Inc. 2025-2026 meeting

220 asset managers disclosed a vote on at least one Spyre Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Spyre Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Cameron Turtle, D. Phil.

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 7 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 66,176,245WITHHELD: 761,953
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Cameron Turtle, D.Phil.

Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Cameron Turtle, D. Phil.”): 66,176,245 for, 761,953 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Election of Class I Directors for terms expiring in 2029: Cameron Turtle, D.Phil.” at Spyre Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,366,9620 00For
Vanguard3,604,7000 10For
Capital Group2,412,6930 00For
BlackRock2,015,8080 00For
T. Rowe Price1,262,1660 00For
State Street658,5960 00For
Charles Schwab561,7670 00For
JPMorgan524,1550 00For
DRIEHAUS MUTUAL FUNDS414,7590 00For
Victory Capital326,8010 00For
FRANKLIN STRATEGIC SERIES323,5840 00For
RBB FUND, INC.65,2740 0252,945Mixed
First Trust178,1350 00For
Hartford168,8930 00For
Principal4,2990 0155,168Withhold
Equitable157,7550 00For
TIAA144,9240 00For
TRUST FOR PROFESSIONAL MANAGERS82,0620 00For
Brighthouse76,0360 00For
Northwestern Mutual74,1260 00For
Jackson National67,1700 00For
John Hancock60,9590 00For
Lincoln Financial52,6740 00For
Columbia Threadneedle49,3110 00For
AIG/SunAmerica43,6360 00For

Fund voting reports, all 67 managers: 23,088,662 for, 411,671 withheld, 1 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Election of Class I Directors for terms expiring in 2029: Cameron Turtle, D.Phil.” at Spyre Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Remedium Capital Partners, LLC1,456,2310 00For

Institutional-manager reports, all 1 managers: 1,456,231 for.

Elect Director: Laurie Stelzer

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 7 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD
FOR: 56,954,664WITHHELD: 9,983,534
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Laurie Stelzer

Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Laurie Stelzer”): 56,954,664 for, 9,983,534 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Election of Class I Directors for terms expiring in 2029: Laurie Stelzer” at Spyre Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,366,9620 00For
Vanguard3,602,0110 152,674For
Capital Group2,412,6930 00For
BlackRock2,015,8080 00For
T. Rowe Price1,262,1660 00For
State Street1,3840 0657,212Withhold
Charles Schwab561,7670 00For
JPMorgan524,1550 00For
DRIEHAUS MUTUAL FUNDS00 0414,759Withhold
Victory Capital00 0326,801Withhold
FRANKLIN STRATEGIC SERIES323,5840 00For
RBB FUND, INC.00 0318,219Withhold
First Trust00 0178,135Withhold
Hartford168,8930 00For
Principal00 0159,467Withhold
Equitable112,8250 044,930Mixed
TIAA144,9240 00For
TRUST FOR PROFESSIONAL MANAGERS00 82,0620Abstain
Brighthouse53,6250 022,411Mixed
Northwestern Mutual74,1260 00For
Jackson National00 67,1700Abstain
John Hancock42,6920 18,2670Mixed
Lincoln Financial7,2740 045,400Mixed
Columbia Threadneedle00 049,311Withhold
AIG/SunAmerica00 043,636Withhold

Fund voting reports, all 67 managers: 20,823,005 for, 2,495,688 withheld, 181,641 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Election of Class I Directors for terms expiring in 2029: Laurie Stelzer” at Spyre Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Remedium Capital Partners, LLC1,456,2310 00For

Institutional-manager reports, all 1 managers: 1,456,231 for.

Elect Director: Mark McKenna

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 8 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 65,608,709WITHHELD: 1,329,489
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Mark McKenna

Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Mark McKenna”): 65,608,709 for, 1,329,489 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Election of Class I Directors for terms expiring in 2029: Mark McKenna” at Spyre Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,366,9620 00For
Vanguard3,604,6990 20For
Capital Group2,412,6930 00For
BlackRock2,015,8080 00For
T. Rowe Price1,262,1660 00For
State Street658,4060 0190For
Charles Schwab561,7670 00For
JPMorgan524,1550 00For
DRIEHAUS MUTUAL FUNDS414,7590 00For
Victory Capital326,8010 00For
FRANKLIN STRATEGIC SERIES323,5840 00For
RBB FUND, INC.65,2740 0252,945Mixed
First Trust178,1350 00For
Hartford168,8930 00For
Principal4,2990 0155,168Withhold
Equitable112,8250 044,930Mixed
TIAA144,9240 00For
TRUST FOR PROFESSIONAL MANAGERS82,0620 00For
Brighthouse76,0360 00For
Northwestern Mutual74,1260 00For
Jackson National67,1700 00For
John Hancock60,9590 00For
Lincoln Financial52,6740 00For
Columbia Threadneedle49,3110 00For
AIG/SunAmerica43,6360 00For

Fund voting reports, all 67 managers: 23,043,540 for, 456,791 withheld, 2 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Election of Class I Directors for terms expiring in 2029: Mark McKenna” at Spyre Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Remedium Capital Partners, LLC1,456,2310 00For

Institutional-manager reports, all 1 managers: 1,456,231 for.

To approve the company's amended and restated 2016 employee stock purchase plan.

No official matchCOMPENSATION

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 68 asset managers

Description as filed by funds: TO APPROVE THE COMPANY'S AMENDED AND RESTATED 2016 EMPLOYEE STOCK PURCHASE PLAN.

The 68 asset managers below reported 23,490,367 for, 10,401 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 23,490,367AGAINST: 10,401
Largest asset managers voting on “TO APPROVE THE COMPANY'S AMENDED AND RESTATED 2016 EMPLOYEE STOCK PURCHASE PLAN.” at Spyre Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,366,9620 00For
Vanguard3,599,1125,589 00For
Capital Group2,412,6930 00For
BlackRock2,015,8080 00For
T. Rowe Price1,262,1660 00For
State Street657,711885 00For
Charles Schwab561,7670 00For
JPMorgan524,1550 00For
DRIEHAUS MUTUAL FUNDS414,7590 00For
Victory Capital326,8010 00For
FRANKLIN STRATEGIC SERIES323,5840 00For
RBB FUND, INC.318,2190 00For
First Trust178,1350 00For
Hartford168,8930 00For
Principal159,4670 00For
Equitable157,7550 00For
TIAA144,9240 00For
TRUST FOR PROFESSIONAL MANAGERS82,0620 00For
Brighthouse76,0360 00For
Northwestern Mutual74,1260 00For
Jackson National67,1700 00For
John Hancock60,9590 00For
Lincoln Financial52,6740 00For
Columbia Threadneedle49,3110 00For
AIG/SunAmerica43,6360 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

On a non-binding, advisory basis, the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 62,075,459AGAINST: 4,760,373

Prior year: 93.2% for (May 29, 2025 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 220 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Spyre Therapeutics, Inc.’s own tally for this item (“2. On a non-binding, advisory basis, the compensation of the Company's named executive officers”): 62,075,459 for, 4,760,373 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Spyre Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,366,9620 00For
Vanguard3,602,0182,682 00For
Capital Group02,412,693 00Against
BlackRock2,015,8080 00For
T. Rowe Price1,262,1660 00For
State Street658,327269 00For
Charles Schwab0561,767 00Against
JPMorgan524,1550 00For
DRIEHAUS MUTUAL FUNDS414,7590 00For
Victory Capital326,8010 00For
FRANKLIN STRATEGIC SERIES323,5840 00For
RBB FUND, INC.318,2190 00For
First Trust178,1350 00For
Hartford168,8930 00For
Principal159,4670 00For
Equitable157,7550 00For
TIAA144,9240 00For
TRUST FOR PROFESSIONAL MANAGERS82,0620 00For
Brighthouse76,0360 00For
Northwestern Mutual74,1260 00For
Jackson National67,1700 00For
John Hancock60,9590 00For
Lincoln Financial52,6740 00For
Columbia Threadneedle49,3110 00For
AIG/SunAmerica43,6360 00For

Fund voting reports, all 67 managers: 20,419,744 for, 3,077,031 against, 3,558 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 170 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Spyre Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity11,224,2150 00For
RTW INVESTMENTS, LP4,191,3640 00For
Fairmount Funds Management LLC4,018,1010 00For
Venrock Adviser, LLC3,685,4480 00For
PERCEPTIVE ADVISORS LLC2,587,4910 00For
Capital Group02,412,693 00Against
Commodore Capital LP1,806,4630 00For
State Street1,702,47810,432 00For
T. Rowe Price1,700,5040 00For
DRIEHAUS CAPITAL MANAGEMENT LLC1,666,3780 00For
RA CAPITAL MANAGEMENT, L.P.1,621,6200 00For
GEODE CAPITAL MANAGEMENT, LLC1,593,6870 00For
Polar Capital Holdings Plc1,499,6620 00For
Remedium Capital Partners, LLC1,456,2310 00For
Wellington1,070,3330 00For
BRAIDWELL LP932,8230 00For
FRANKLIN ADVISERS INC879,5010 00For
Siren, L.L.C.818,5980 00For
BlackRock660,1287,794 00For
Caligan Partners LP662,8320 00For
Affinity Asset Advisors, LLC591,2860 00For
Charles Schwab0562,659 00Against
Vanguard543,0110 00For
Paradigm Biocapital Advisors LP518,0540 00For
Candriam S.C.A.0456,582 00Against

Institutional-manager reports, all 170 managers: 49,049,364 for, 4,290,166 against, 5,692 abstained, 696 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December…

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 68,430,566AGAINST: 670

Prior year: 99.9% for (May 29, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.

Spyre Therapeutics, Inc.’s own tally for this item (“3. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 68,430,566 for, 670 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE Y” at Spyre Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,366,9620 00For
Vanguard3,604,7010 00For
Capital Group2,412,6930 00For
BlackRock2,015,8080 00For
T. Rowe Price1,262,1660 00For
State Street658,5960 00For
Charles Schwab561,7670 00For
JPMorgan524,1550 00For
DRIEHAUS MUTUAL FUNDS414,7590 00For
Victory Capital326,8010 00For
FRANKLIN STRATEGIC SERIES323,5840 00For
RBB FUND, INC.318,2190 00For
First Trust178,1350 00For
Hartford168,8930 00For
Principal159,4670 00For
Equitable157,7550 00For
TIAA144,9240 00For
TRUST FOR PROFESSIONAL MANAGERS82,0620 00For
Brighthouse76,0360 00For
Northwestern Mutual74,1260 00For
Jackson National67,1700 00For
John Hancock60,9590 00For
Lincoln Financial52,6740 00For
Columbia Threadneedle49,3110 00For
AIG/SunAmerica43,6360 00For

Fund voting reports, all 67 managers: 23,496,776 for, 3,558 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE Y” at Spyre Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Remedium Capital Partners, LLC1,456,2310 00For

Institutional-manager reports, all 1 managers: 1,456,231 for.

Largest Spyre Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 78,839,858 shares outstanding at the time of that meeting.

Fund voting reports: top Spyre Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 11.88%
2Vanguard 4.57%
3Capital Group 3.06%
4BlackRock 2.56%
5T. Rowe Price 1.60%
6State Street 0.84%
7Charles Schwab 0.71%
8JPMorgan 0.66%
9DRIEHAUS MUTUAL FUNDS 0.53%
10Victory Capital 0.41%
Institutional-manager reports: top Spyre Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 14.24%
2RTW INVESTMENTS, LP 5.32%
3Fairmount Funds Management LLC 5.10%
4Venrock Adviser, LLC 4.67%
5PERCEPTIVE ADVISORS LLC 3.28%
6Capital Group 3.06%
7Commodore Capital LP 2.29%
8State Street 2.17%
9T. Rowe Price 2.16%
10DRIEHAUS CAPITAL MANAGEMENT LLC 2.11%

Reported Spyre Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Spyre Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)11,781,024 14.94%Form 13F, quarter ended March 31, 2026
Peter Harwin9,016,702 11.44%Schedule 13D, filed April 20, 2026
Tomas Kiselak8,787,215 11.15%Proxy statement (DEF 14A), table as of February 12, 2026
Fairmount Healthcare Fund II L.P.8,271,021 10.49%Proxy statement (DEF 14A), table as of February 12, 2026
FMR LLC7,623,881 9.67%Proxy statement (DEF 14A), table as of February 12, 2026
BlackRock5,521,221 7.00%Form 13F, quarter ended March 31, 2026
Perceptive Advisors LLC4,319,496 5.48%Schedule 13G, filed August 14, 2026
RTW Investments, LP4,251,996 5.39%Schedule 13G, filed August 14, 2026
Vanguard Group4,035,074 5.12%Form 13F, quarter ended March 31, 2026
State Street2,607,031 3.31%Form 13F, quarter ended March 31, 2026

Percentages above are of 78,839,858 shares outstanding, as reported by Spyre Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Spyre Therapeutics, Inc.'s shareholder meeting held May 27, 2026, in the 2025-2026 proxy season, 220 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,672 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — Spyre Therapeutics, Inc.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Spyre Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Spyre Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Spyre Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Spyre Therapeutics (SYRE) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/spyre-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.